Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

Daniela Dobre; Jeffrey S. Borer; Kim Fox; Karl Swedberg; Kirkwood F. Adams; John G.F. Cleland; Alain Cohen-Solal; Mihai Gheorghiade; Francois Gueyffier; Christopher M. O'Connor; Mona Fiuzat; Athul Patak; Ileana L. Piña; Giuseppe Rosano; Hani N. Sabbah; Luigi Tavazzi; Faiez Zannad

doi:10.1093/eurjhf/hft129

Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

Daniela Dobre, Jeffrey S. Borer, Kim Fox, Karl Swedberg, Kirkwood F. Adams, John G.F. Cleland, Alain Cohen-Solal, Mihai Gheorghiade, Francois Gueyffier, Christopher M. O'Connor, Mona Fiuzat, Athul Patak, Ileana L. Piña, Giuseppe Rosano, Hani N. Sabbah, Luigi Tavazzi, Faiez Zannad

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.

Original language	English (US)
Pages (from-to)	76-85
Number of pages	10
Journal	European Journal of Heart Failure
Volume	16
Issue number	1
DOIs	https://doi.org/10.1093/eurjhf/hft129
State	Published - Jan 2014
Externally published	Yes

Keywords

Amiodarone
Beta-blockers
Chronic heart failure
Digoxin
Heart rate
Heart rate-lowering drugs
Ivabradine
Verapamil

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1093/eurjhf/hft129

Cite this

Dobre, D., Borer, J. S., Fox, K., Swedberg, K., Adams, K. F., Cleland, J. G. F., Cohen-Solal, A., Gheorghiade, M., Gueyffier, F., O'Connor, C. M., Fiuzat, M., Patak, A., Piña, I. L., Rosano, G., Sabbah, H. N., Tavazzi, L., & Zannad, F. (2014). Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. European Journal of Heart Failure, 16(1), 76-85. https://doi.org/10.1093/eurjhf/hft129

Dobre, D, Borer, JS, Fox, K, Swedberg, K, Adams, KF, Cleland, JGF, Cohen-Solal, A, Gheorghiade, M, Gueyffier, F, O'Connor, CM, Fiuzat, M, Patak, A, Piña, IL, Rosano, G, Sabbah, HN, Tavazzi, L & Zannad, F 2014, 'Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties', European Journal of Heart Failure, vol. 16, no. 1, pp. 76-85. https://doi.org/10.1093/eurjhf/hft129

@article{e5318122488f45639d7e97cf0734a830,

title = "Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties",

abstract = "Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.",

keywords = "Amiodarone, Beta-blockers, Chronic heart failure, Digoxin, Heart rate, Heart rate-lowering drugs, Ivabradine, Verapamil",

author = "Daniela Dobre and Borer, {Jeffrey S.} and Kim Fox and Karl Swedberg and Adams, {Kirkwood F.} and Cleland, {John G.F.} and Alain Cohen-Solal and Mihai Gheorghiade and Francois Gueyffier and O'Connor, {Christopher M.} and Mona Fiuzat and Athul Patak and Pi{\~n}a, {Ileana L.} and Giuseppe Rosano and Sabbah, {Hani N.} and Luigi Tavazzi and Faiez Zannad",

year = "2014",

month = jan,

doi = "10.1093/eurjhf/hft129",

language = "English (US)",

volume = "16",

pages = "76--85",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Heart rate

T2 - A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

AU - Dobre, Daniela

AU - Borer, Jeffrey S.

AU - Fox, Kim

AU - Swedberg, Karl

AU - Adams, Kirkwood F.

AU - Cleland, John G.F.

AU - Cohen-Solal, Alain

AU - Gheorghiade, Mihai

AU - Gueyffier, Francois

AU - O'Connor, Christopher M.

AU - Fiuzat, Mona

AU - Patak, Athul

AU - Piña, Ileana L.

AU - Rosano, Giuseppe

AU - Sabbah, Hani N.

AU - Tavazzi, Luigi

AU - Zannad, Faiez

PY - 2014/1

Y1 - 2014/1

N2 - Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.

AB - Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (riskfactor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bra-dycardic agent.

KW - Amiodarone

KW - Beta-blockers

KW - Chronic heart failure

KW - Digoxin

KW - Heart rate

KW - Heart rate-lowering drugs

KW - Ivabradine

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=84896943402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896943402&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hft129

DO - 10.1093/eurjhf/hft129

M3 - Article

C2 - 23928650

AN - SCOPUS:84896943402

SN - 1388-9842

VL - 16

SP - 76

EP - 85

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 1

ER -

Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this